Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications.
D000341:Affective Disorders, Psychotic / Q000188:drug therapy*; D000818:Animals; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D001714:Bipolar Disorder / Q000188:drug therapy; D002220:Carbamazepine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D016651:Lithium Carbonate; D011618:Psychotic Disorders / Q000188:drug therapy; D011619:Psychotropic Drugs; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D016651:Lithium Carbonate; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D008094:Lithium; D002746:Chlorpromazine